期刊
CURRENT RHEUMATOLOGY REPORTS
卷 13, 期 1, 页码 51-58出版社
SPRINGER
DOI: 10.1007/s11926-010-0146-6
关键词
Imatinib; Systemic sclerosis; Scleroderma; Fibrosis; Tyrosine kinase inhibitor
类别
资金
- Scleroderma Foundation
- Clinical and Translational Science Center at Weill Cornell Medical Center [UL1RR024996]
- Rudolph Rupert Scleroderma Program
Imatinib mesylate has become a therapy of interest for the treatment of systemic sclerosis because of its ability to inhibit c-Abl and platelet-derived growth factor receptor, tyrosine kinases involved in profibrotic pathways. Preclinical data using in vitro and murine models of fibrosis have demonstrated the antifibrotic properties of imatinib. Imatinib is currently used widely in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other conditions, and a large amount of information is available regarding the safety of the medication in these patient populations. Whether imatinib will be tolerable or effective in the treatment of systemic sclerosis is the subject of several investigations. The aim of this review is to summarize this body of research to date.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据